Teva's Reslizumab Gets Panel Nod For Adult Asthma, Unanimous 'No' For Adolescents
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee vote reminiscent of earlier review of GlaxoSmithKline's mepolizumab, which ended up with adolescent claim anyway.